20.23
Schlusskurs vom Vortag:
$20.43
Offen:
$20.19
24-Stunden-Volumen:
48,301
Relative Volume:
1.42
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.75%
1M Leistung:
-2.46%
6M Leistung:
-18.16%
1J Leistung:
-14.64%
Ishares Genomics Immunology And Healthcare Etf Stock (IDNA) Company Profile
Firmenname
Ishares Genomics Immunology And Healthcare Etf
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IDNA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IDNA
Ishares Genomics Immunology And Healthcare Etf
|
20.23 | 0 | 0 | 0 | 0 | 0.00 |
![]()
VTI
Vanguard Total Stock Market Etf
|
289.88 | 417.53B | 0 | 0 | 0 | 0.00 |
![]()
SPY
Spdr S P 500 Etf Trust
|
589.39 | 372.57B | 0 | 0 | 0 | 0.00 |
![]()
IVV
Ishares Core S P 500 Etf
|
592.15 | 253.41B | 0 | 0 | 0 | 0.00 |
![]()
VB
Vanguard Small Cap Etf
|
228.19 | 160.59B | 0 | 0 | 0 | 0.00 |
![]()
QQQ
Invesco Qqq Trust Series 1
|
519.11 | 124.43B | 0 | 0 | 0 | 0.00 |
Ishares Genomics Immunology And Healthcare Etf Aktie (IDNA) Neueste Nachrichten
Objective long/short (XDNA) Report (XDNA:CA) - news.stocktradersdaily.com
(XDNA) Trading Advice (XDNA:CA) - news.stocktradersdaily.com
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal - Benzinga
(XDNA) Stock Trading Blueprint (XDNA:CA) - news.stocktradersdaily.com
Is Healthcare Losing the Status of Safe Haven? ETFs in Focus - Zacks Investment Research
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion - Benzinga
IDNA: The Cutting Edge Of Medical Science Is A Risky Investment (NYSEARCA:IDNA) - Seeking Alpha
7 Best-Performing Biotech ETFs for March 2025 - NerdWallet
Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm? - Benzinga
Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies - Benzinga
Future Health: Harnessing Innovations In Healthcare - Syfe
Thematic Portfolios Re-optimisation – Capturing Emerging Trends and Maximising Growth Potential - Syfe
The Healthcare Sector: 5 Things To Know - Syfe
5 Best ETFs Tracking CRISPR Gene Editing - The Motley Fool
7 Best Biotech ETFs In Canada for March 2025 - Wealth Awesome
Has Biotechnology Bottomed Out? - Master Investor
3 Healthcare Technology Stocks to Improve Lives in 2024 - InvestorPlace
IDNA ETF: Continues To Underperform, But With Long Run Potential - Seeking Alpha
Megatrends: Gene Therapy and Editing - Money/ US News
StockWatch: Top Biotech ETFs (Mostly) Sink Faster than the Market During Q1 - Genetic Engineering & Biotechnology News
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector - InvestorPlace
3 Themes Growth and Tech Investors May Want to Consider in 2023 - Nasdaq
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher - InvestorPlace
Biotech ETFs Slip After Novavax Cuts 2022 Guidance - ETF Trends
3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort - The Motley Fool
3 genome ETFs to watch in 2021 - CMC Markets
iShares Genomics Immunology And Healthcare ETF, Overshadowed But Not Irrelevant (NYSEARCA:IDNA) - Seeking Alpha
3 ETFs For More Moderna Bets - Yahoo
iShares Lists Cybersecurity and Genomics ETFs - ETF Trends
BlackRock lists genomics and cyber security ETFs - ETF Stream
Top Healthcare ETFs Right Now • Updated Daily - Benzinga
Finanzdaten der Ishares Genomics Immunology And Healthcare Etf-Aktie (IDNA)
Es liegen keine Finanzdaten für Ishares Genomics Immunology And Healthcare Etf (IDNA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):